United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
United Therapeutics reported Q2 2026 revenue of $783.3 million, down 2% year-over-year, with declines in Nebulized Tyvaso and Remodulin offsetting growth in Tyvaso DPI. Diluted EPS increased to $7.27 from $6.41 a year ago, driven by a lower effective tax rate of 11% and significant share repurchases under a $2 billion authorization.
Key figures
- Eps
- 7.27
- Revenue
- 783300000
- Guidance
- Expects potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH by next year; expects Tyvaso DPI to follow into IPF and then PPF
- Net income
- 333000000
- Rd expense
- 146300000
- Operating income
- 330800000
- Unituxin revenue
- 65200000
- Orenitram revenue
- 125700000
- Remodulin revenue
- 126300000
- Effective tax rate
- 11%
- Tyvaso dpi revenue
- 326600000
- Total tyvaso revenue
- 452600000
- Nebulized tyvaso revenue
- 126000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.